Abstract
BACKGROUND: Decision-support tools quantify the risk of undiagnosed cancer in symptomatic patients, and may help GPs when making referrals. AIM: To quantify the availability and use of cancer decision-support tools (QCancer(®) and risk assessment tools) and to explore the association between tool availability and 2-week-wait (2WW) referrals for suspected cancer. DESIGN AND SETTING: A cross-sectional postal survey in UK primary care. METHODS: Out of 975 UK randomly selected general practices, 4600 GPs and registrars were invited to participate. Outcome measures included the proportions of UK general practices where cancer decision-support tools are available and at least one GP uses the tool. Weighted least-squares linear regression with robust errors tested the association between tool availability and number of 2WW referrals, adjusting for practice size, sex, age, and Index of Multiple Deprivation. RESULTS: In total, 476 GPs in 227 practices responded (response rates: practitioner, 10.3%; practice, 23.3%). At the practice level, 83/227 (36.6%, 95% confidence interval [CI] = 30.3 to 43.1) practices had at least one GP or registrar with access to cancer decision-support tools. Tools were available and likely to be used in 38/227 (16.7%, 95% CI = 12.1 to 22.2) practices. In subgroup analyses of 172 English practices, there was no difference in mean 2WW referral rate between practices with tools and those without (mean adjusted difference in referrals per 100 000: 3.1, 95% CI = -5.5 to 11.7). CONCLUSION: This is the first survey of cancer decision-support tool availability and use. It suggests that the tools are an underused resource in the UK. Given the cost of cancer investigation, a randomised controlled trial of such clinical decision-support aids would be appropriate.